Gemini Therapeutics, Inc. (GMTX)

$1.35

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol GMTX
Price $1.35
Beta -0.125
Volume Avg. 0.02M
Market Cap 58.493M
Shares () -
52 Week Range 1.35-27.1
1y Target Est -
DCF Unlevered GMTX DCF ->
DCF Levered GMTX LDCF ->
ROE -38.78% Strong Sell
ROA -40.95% Strong Sell
Operating Margin -
Debt / Equity 1.40% Neutral
P/E -
P/B 0.56 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GMTX news


Healthcare
Biotechnology
NASDAQ Global Market

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.